Concurrent chemoradiotherapy with new platinum compound nedaplatin in oral cancer

Oral Oncology

Volumn 39, Issue 2, 2003, Pages 144-149

  Ita, Masamichi ^a   Okafuji, Masaki ^a   Fukuda, Kazuhiko ^a   Mitsuoka, Kouji ^a   Hanakita, Tomoya ^a   Hayatsu, Yoshikazu ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 Fluorouracil (5 Fu); Chemotherapy; Nedaplatin; Oral squamous cell carcinoma; Radiotherapy

Indexed keywords

FLUOROURACIL; NEDAPLATIN; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ERYTHROCYTE; FEMALE; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; MALE; MOUTH CARCINOMA; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 0037293513     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(02)00035-0     Document Type: Article

References (29)

1. Glass J., Silverman C.L., Axelrod R., Corn B.W., Andrews D.W. Fractionated stereotactic radiotherapy with cis-platinum radiosensitization in the treatment of recurrent, progressive, or persistent malignant astrocytoma. Am. J. Clin. Oncol. 20:1997;226-229.
2. Kunitoh H., Akiyama Y., Kusaba H., Yamamoto N., Sekine I., Ohe Y.et al. A phase I/II trial of cisplatin, docetaxel and ifosfamide in advanced or recurrent non-small cell lung cancer. Lung Cancer. 33:2001;259-265.
3. Shimada Y. Clinical trial for advanced gastrointestinal cancers in Japan. Japan Clinical Oncology Group Gastrointestinal Oncology Study Group. Cancer Chemother Pharmacol. 42:1998;82-84.
4. De Lena M., Lorusso V., Latorre A., Fanizza G., Gargano G., Caporusso L.et al. Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. Eur J Cancer. 37:2001;364-368.
5. Fishman A., Chiu J.K., Girtanner R.E., Dennis W., Carpenter L.S., Lu H.H.et al. Phase I-II study of combined 5-fluorouracil and cisplatin chemotherapy and altered fractionation radiotherapy for advanced squamous cell carcinoma of cervix. Am J Clin Oncol. 20:1997;342-347.
6. Jereczek-Fossa B., Braud F.D., Gasparetto M., Pas T.D., Tradati N., Leonardi M.C.et al. Induction chemotherapy followed by simultaneous hyperfractionated radiochemotherapy in advanced head and neck cancer. Strahlenther Onkol. 174:1998;457-461.
7. Robbins K.T., Vicario D., Seagren S., Weisman R., Pellitteri P., Kerber C.et al. A targeted supradose cisplatin chemoradiation protocol for advanced head and neck cancer. Am J Surg. 168:1994;419-422.
8. Depondt J., Gehanno P., Martin M., Lelievre G., Guerrier B., Peytral C.et al. Neoadjuvant chemotherapy with carboplatin/5-fluorouracil in head and neck cancer. Oncology. 50:1993;23-27.
9. Andres L.D., Brunet J., Lopez-Pousa A., Burgues J., Vega M., Tabernero J.M.et al. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol. 13:1995;1493-1550.
10. Fukuda M., Shinkai H., Horiuchi M., Sasaki Y., Tamura T., Obe Y.et al. Phase II study of (glycolato-O,O′) diammineplatinum (II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol. 26:1990;393-396.
11. Yamanaka H., Motohiro T., Michiura T., Asai A., Mori T., Hioki K. Nedaplatin and 5-Fu combined with radiation in the treatment for esophageal cancer. Jpn J Cancer Thorac Cardiovasc Surg. 46:1998;943-948.
12. Akaza H., Togashi M., Nishio Y., Miki T., Kotake T., Matumura Y.et al. Phase II study of cis-diammine (glycolato) platinum, 254S, in patients with advanced germ-cell testicular cancer, prostatic cancer and transitional-cell carcinoma of the urinary tract. 254-S Urological Cancer Study Group. Cancer Chemother Pharmacol. 31:1992;187-192.
13. Kato T., Noda K., Hirabayashi K., Nishimura H. Phase II study of cis-diammine (glycolato) platinum, [254S], a new platinum complex, for gynecological malignancy. Proc 16th Intl Cong Chemother, Anti-cancer Section. 823:1989;1-2.
14. Inuyama Y., Miyake H., Horiuchi M., Hayasaka K., Komiyama S., Ohta K. An early phase II study of cis-diammine glycolato platinum, 254S, for head and neck cancer. Jpn J Cancer Chemother. 19:1992;863-869.
15. Alberts D.S., Fanta P.T., Running K.L., Adair L.P. Jr., Garcia D.J. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254 S), with that of cisplatin and carboplatin against fresh, human ovarian cancers. Cancer Chemother Pharmacol. 39:1997;493-497.
16. Adachi S., Ogasawara T., Wakimoto E., Tsuji Y., Takemura T., Koyama K.et al. Phase I/II study of intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical carcinoma. Cancer. 91:2001;74-79.
17. Vokes E.E., Ratain M.J., Mick R., McEvilly J.M., Haraf D., Kozloff M.et al. Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 11:1993;360-368.
18. Wang H., Wang C., Chen J., Chang H., Kiu M., Liaw C.et al. Cisplatin and 5-fluorouracil as neoadjuvant chemotherapy: predicting response in head and neck squamous cell cancer. J Formos Med Assoc. 94:1995;87-94.
19. Numico G., Benasso M., Vannozzi M.O., Nerlano M., Rosso R., Viale M.et al. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmocokinetic analysis. Anticancer Res. 19:1998;1313-1318.
20. Khan A., Spiro J.D., Dowsett R., Greenberg B.R. Sequential chemotherapy and radiotherapy for organ preservation in advanced resectable nonlaryngeal head and neck cancer. Am J Clin Oncol. 22:1999;403-407.
21. Taylor I.V.S.G., Murthy A.K., Griem K.L., Recine D.C., Kiel K., Blendowski C.et al. Concomitant cisplatin/5-Fu infusion and radiotherapy in advanced head and neck cancer: 8-year analysis of results. Head Neck. 19:1997;684-691.
22. Lavertu P., Adelstein D.J., Saxton J.P., Secic M., Wanamaker J.R., Eliacher I.et al. Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV in squamous cell head and neck cancer. Head Neck. 19:1997;559-566.
23. Benasso M., Bonelli L., Numiko G., Corvo R., Sanguineti G., Rasso R.et al. Treatment with cisplatin and fluorouracil alternating with radiation favourably affects prognosis of inoperable squamous cell carcinoma of the head and neck: results of a multivariate analysis on 273 patients. Ann Oncol. 8:1997;773-779.
24. Wendt T.G., Grabenbauer G.G., Rodel C.M., Thiel H., Aydin H., Rohloff R.et al. Simultaneous radiochemotherapy versus radiotherapy in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol. 4:1998;1318-1324.
25. Taylor I.V.S.G., Murthy A.K., Vannetzel J.M., Colin M., Dray D.D., Caldarelli S.et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol. 12:1994;385-395.
26. Forastiere A.A. Overview of platinum chemotherapy in head and neck cancer. Semin Oncol. 21:1994;20-27.
27. Hanauske A-R., Schilling T., Heinrich B., Kau R., Herzog M., Quasthoff S.et al. Clinical phase I study of paclitaxel followed by cisplatin in advanced head and neck squamous cell carcinoma. Semin Oncol. 22:1995;35-39.
28. Gebbia V.G., Testa A., Gregorio C.D., Ingria F., Valenza R., Cannata G.et al. Vinorelbine plus cisplatin in recurrent or previously untreated squamous cell carcinoma of the head and neck. Am J Clin Oncol. 18:1995;293-296.
29. Shirasaka T., Shimamoto Y., Ohshima H., Yamaguchi M., Kato T., Yonekura K.et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 7:1996;548-557.